Clinical Trial: Efficacy and Safety of AK104 Combined With Chemotherapy and Cetuximab or Bevacizumab

U.S., Nov. 29 -- ClinicalTrials.gov registry received information related to the study (NCT07253896) titled 'Efficacy and Safety of AK104 Combined With Chemotherapy and Cetuximab or Bevacizumab' on Jan. 29, 2024.

Brief Summary: Evaluate the objective response rate (ORR) of AK104 combined with chemotherapy and cetuximab or bevacizumab in second-line treatment of MSS type advanced colorectal cancer

Study Start Date: Jan. 03, 2024

Study Type: INTERVENTIONAL

Condition: Safety

Intervention: DRUG: AK104 and cetuximab or bevacizumab and FOLFIRI

AK104 and cetuximab or bevacizumab and FOLFIRI as the second line

Recruitment Status: RECRUITING

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University

Information provided ...